Provided by Tiger Fintech (Singapore) Pte. Ltd.

Ikena Oncology, Inc.

1.06
-0.0400-3.64%
Post-market: 1.060.00000.00%16:00 EDT
Volume:17.09K
Turnover:18.49K
Market Cap:51.15M
PE:-1.04
High:1.11
Open:1.11
Low:1.02
Close:1.10
Loading ...

Company Profile

Company Name:
Ikena Oncology, Inc.
Exchange:
NASDAQ
Establishment Date:
2016
Employees:
10
Office Location:
645 Summer Street,Suite 101,Boston,Massachusetts,United States
Zip Code:
02210
Fax:
- -
Introduction:
Ikena Oncology, Inc. operates as an oncology company that develops precision medicines to biomarker-defined patients with specific unmet needs in the United States. Its lead oncology product candidate is IK-930, a paralog selective inhibitor of the transcriptional enhanced associate domain, a transcription factor in the Hippo signaling pathway. It also develops IK-595, designed to trap MEK and RAF for inhibiting RAS signals than existing inhibitors; and IK-175, a monotherapy and in combination with nivolumab in patients with advanced or metastatic solid tumors, including urothelial carcinomas. Ikena Oncology, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

Directors

Name
Position
Mark Manfredi
President, Chief Executive Officer and Director
Ronald C. Renaud, Jr.
Chairman and Director
David Bonita
Director
Iain D. Dukes
Director
Jean Francois Formela
Director
Otello Stampacchia
Director

Shareholders

Name
Position
Mark Manfredi
President, Chief Executive Officer and Director
Douglas R. Carlson
Chief Operating Officer & Executive Vice President of Finance
Jeffrey Ecsedy
Chief Scientific Officer
Maude Tessier
Chief Business Officer
Sergio Santillana
Chief Medical Officer